Our Solutions   Paclitero- 260 mg Injection

Paclitero- 260 mg Injection

Paclitero 260Mg Injection

*To be consumed as directed by physician.

Therapies:

Anti Neoplastics

Composition:

Paclitaxel

About Paclitero 260Mg Injection

Paclitero 260 mg injection is a prescription medicine that contains paclitaxel 260 mg and is commonly used to treat breast cancer, non-small lung cancer and pancreatic cancer. This injection blocks replication of DNA in the cancer cells by eradicating the need for certain solvents. The injection is administered only under medical supervision as part of a personalised chemotherapy treatment.

Paclitero 260Mg Injection

*To be consumed as directed by physician.


Usage Instructions

  • Paclitero -260 mg injection should only be administered by a certified physician in an oncology clinic or hospital.
  • The dosage and treatment schedule depend on the type of cancer and the patient’s medical history.
  • Regular monitoring through blood tests and clinical assessments is necessary during treatment.
  • Do not miss the scheduled appointments and never self-administer this drug without consultation.

Benefits and Use

  • Paclitero- 260 mg injection helps to treat breast cancer and is used alone or in combination with other drugs during chemotherapy.
  • Nab Paclitero -100 mg Injection helps slow or stop the growth of cancer cells by interfering with their ability to divide and multiply.
  • It is commonly used in the treatment of breast cancer, non-small cell lung cancer, pancreatic cancer, and other cancers.
  • The albumin-bound formulation supports targeted drug delivery and may improve treatment efficiency while reducing exposure to solvent-related complications associated with conventional paclitaxel formulations.

Safety Information

  • Alcohol:
  • Alcohol is not recommended while administering an injection as it may intensify certain side effects such as nausea, immunosuppression, and fatigue. Patients with a history of alcoholism should disclose this to their physician before starting the treatment.
  • Pregnancy:
  • Nab Paclitero- 260 mg injection is generally not recommended during pregnancy as it may harm the developing baby. Inform your doctor if you are planning a pregnancy or if you are planning to conceive.
  • Breastfeeding:
  • Breastfeeding mothers are not recommended to administer this drug as it may pass into breast milk. Patients should consult their oncologist if they are feeding infants.
  • Kidney Disorders:
  • Patients with mild to moderate renal impairment may receive this injection with caution and close monitoring by their physician. Dosage adjustments are required for patients with severe kidney dysfunction.
  • Liver Disorders:
  • Nab Paclitaxel -260mg Injection should be used with caution in patients with mild to moderate hepatic impairment, as reduced liver function may affect drug metabolism and increase the risk of toxicity.

Ingredients

Paclitaxel 260 mg

How to Use

  • Nab Paclitero- 260mg Injection is administered as an intravenous infusion by a trained healthcare professional.
  • Your oncologist determines the infusion duration and frequency based on your treatment protocol.
  • Regular follow-up appointments and laboratory monitoring help ensure the treatment remains safe and effective throughout your chemotherapy course.

Storage Information

Refrigerate below 30°C